Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for patent JP 7232845 titled "METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL". This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101, a lead investigational product. The patent is valid till 2039.
Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutics, commented, "We're excited to have this patent in Japan. Expansion of our patent portfolio further supports our global clinical programs. This patent is the outcome of the dedicated efforts of our valued long-term partner Syngene International Ltd. in helping us achieve this important goal." First issued in the United States in 2021, this patent covers a shorter synthesis of SBP-101, which provides many benefits including: 1) the ability to manufacture product with a reduced lead time 2) quicker access to drug supply facilitating expansion into additional indications and 3) enables a scalable, efficient and cost-effective manufacturing process for future commercialization.
Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Ltd., said, "We have been partnering with Panbela for the last decade, and I am proud of the work achieved through the successful collaboration. In this case, reducing the number of steps in production and simplifying the manufacturing process means that the drug will reach patients faster. The protection of SBP-101 production through patents in the U.S. and now in Japan are significant milestones."
Dr. Simpson added, "The Company expects to continue innovation and patent portfolio building to support our clinical programs. This process in this patent utilizes a pharmaceutical starting material that is widely available, increasing the availability of drug supply moving forward. "